Effectiveness of Brief Behavioral Intervention for Insomnia on Anxiety, Depression, Quality of Life, and Sleep: A Randomized Pilot Trial Authors: Horacio Balam Alvarez Garcia, Ulises Jimenez Correa, Alejandro Jiménez Genchi Published: 2026 ABSTRACT IntroductionSleep disorders and psychiatric diseases are public health problems that have increased due to the COVID-19 lockdown. In Mexico, telemedicine was a frequently used treatment modality under the circumstances of the lockdown. The present study aimed to test the effectiveness of brief behavioral intervention for improving symptoms of insomnia, anxiety, and depression and increasing quality of life in patients who survived the COVID-19 infection.MethodA randomized, parallel-group equivalence clinical trial was conducted without a passive control group. Pre-treatment, post-treatment, and three-month follow-up measurements were taken. The intervention consisted of four weekly sessions lasting 50 minutes each. Five questionnaires were applied: Insomnia Severity Index (ISI), Pittsburgh Sleep Quality Index (PSQI), General Anxiety Disorder 7 (GAD-7), Patient Health Questionnaire 9 (PHQ-9), SF-36 Health Questionnaire (SF36), and a sleep diary.ResultsIn both therapy modalities, significant improvement was identified (p < 0.05) in ISI (14.57 vs 5.57), ICSP (12.43 vs 4.86), GAD-7 (13.00 vs 5.29), PHQ-9 (15.86 vs 5.00), and SF-36 (30.00 vs 77.14) scores, which coincided with sleep diary measurements.ConclusionBoth intervention modalities were effective, indicating that teleconsultation is a viable treatment option for insomnia symptoms and mental health comorbidities. Introduction During the COVID-19 pandemic, telemedicine became the most widely used treatment modality due to the multiple benefits involved, especially in terms of reducing the risk of contagion during the lockdown [1]. In addition, it has been observed that online therapy is effective for some mental disorders beyond the context of the pandemic [2]. In sleep medicine, telemedicine has shown effectiveness for the management of disorders such as insomnia and obstructive sleep apnea, both in the general population and in COVID-19 survivors [3-5]. Telemedicine applied to sleep disorders has focused on cognitive behavioral therapy for insomnia (CBT-I) and therapeutic adherence to the continuous positive airway pressure (CPAP) device [6,7]. CBT-I is a structured treatment of four to eight sessions in which behavioral techniques (sleep restriction, stimulus control therapy, progressive muscle relaxation), cognitive techniques (cognitive restructuring, paradoxical intention, attentional control), and educational techniques (sleep hygiene) are applied with the aim of controlling the triggers and maintenance of insomnia [8]. This treatment has been shown to be effective in various teleconsultation modalities (live video, remote patient monitoring, or mobile applications) and has therefore been proposed as the first-choice treatment for insomnia [9-12]. In developing countries, research related to tele-health effectiveness has begun to gain importance due to the advantages that this modality presents in public health services, such as the reduction in patient commuting and providing health services to remote communities [13], as well as a decrease in costs. In the case of Mexico, it has been observed that teleconsultation has been effective for addressing psychiatric symptoms such as anxiety and depression [14]. However, no randomized clinical trials (RCTs) of any kind (pilot, equivalence, superiority, or non-inferiority) have been carried out to evaluate the effectiveness of teleconsultation for patients with insomnia and psychiatric symptomatology such as anxiety, depression, or post-traumatic stress disorder [15], representing a knowledge gap [16]. A high prevalence and persistence of insomnia symptoms have been reported in individuals who survived SARS-CoV-2 infection. In a study by Kyzar et al., the prevalence was estimated at 50% that decreased slightly to 42% at a second evaluation, with more severe symptoms of anxiety and depression strongly associated with higher scores on the Insomnia Severity Index (ISI) [17]. In this context, it is necessary to address insomnia symptoms in patients who have recovered from SARS-CoV-2, many of whom were exposed to significant stress or trauma during the illness, to prevent the potential progression of symptoms to more severe conditions such as post-traumatic stress disorder (PTSD) [18]. The aim of this study was, therefore, to test the effectiveness of the Brief Behavioral Intervention for Insomnia (BBII) administered in traditional face-to-face form or by tele-consultation, on symptoms of insomnia, anxiety, depression, and quality of life of patients who survived COVID-19 in Mexico City. The working hypothesis was that BBII would be effective in reducing symptoms of insomnia, anxiety, and depression, as well as improving quality of life in both administration modalities. This was based on trends in the literature indicating that teleconsultation modalities have had good results in multiple clinical, equivalence, and non-inferiority trials. Materials and methods This was a randomized, parallel-group equivalence clinical trial without a passive control group. Pre-treatment, post-treatment, and three-month follow-up data were collected. The study was approved by the Ethics Committee of Hospital General de Mexico "Dr. Eduardo Liceaga" (approval number: DI/23/UME/03/9) and registered at clinicaltrials.gov (NCT05951803) [19]. Study population Eligibility Criteria Participants were recruited from the Hospital General de Mexico "Dr. Eduardo Liceaga" in Mexico City, Mexico, primarily from areas with a high incidence of patients presenting with insomnia, depression, or anxiety. The sample consisted mainly of family members of hospitalized patients who visited the clinic for insomnia symptoms. During the initial interview, the severity of the symptoms was assessed, and if necessary, referrals were made to a highly specialized service (such as psychiatry) within the same hospital. The inclusion criteria were: (i) Medical history of COVID-19 diagnosed by polymerase chain reaction (PCR) or antigen test, (ii) Mild, moderate, symptoms of insomnia, anxiety, or depression (but without a psychiatric diagnosis of anxiety or depression), (iii) Age between 18 and 40 years, and (iv) Access to a computer, tablet, or smartphone with internet service. The exclusion criteria included: (i) Psychological treatment for insomnia, anxiety, or depression during the study, (ii) Cardiorespiratory or neurological sequelae due to COVID-19 that would prevent the participant from taking the BBII test, (iii) Symptoms of another sleep disorder, such as obstructive sleep apnea, restless legs syndrome, or shift work sleep disorder, and (iv) Use of addictive substances (such as tobacco, cannabis, or cocaine). Finally, the withdrawal criteria used were the following: (i) Desire to discontinue BBII therapy, (ii) Missed two consecutive treatment sessions, and (iii) Started pharmacological treatment for anxiety, depression, or insomnia. Sample Size The originally estimated sample size was 34 participants; however, only 17 met all inclusion criteria and provided informed consent. The analysis was thus performed using the available sample, following the recommendation of the supervising research team. Given the pilot nature of this study, formal justification of the sample size based on statistical power was not the primary criterion; rather, the sample size was justified for feasibility reasons, as pilot trials are designed to assess the feasibility of recruitment procedures, protocol adherence, and to generate preliminary effect size estimates that can inform the design of future, fully powered equivalence trials. Interventions BBII was implemented in two different modalities: (i) teleconsultation (BBII-TC), and (ii) traditional in-person sessions (BBII-FF). Participants in the BBII-TC group received four treatment sessions in which they were instructed on the techniques described above. Each session lasted 50 minutes and was scheduled weekly via the institutional platform Zoom (Zoom Communications, Inc., San Jose, California, United States) to ensure session privacy. On the other hand, participants in the BBII-FF received four face-to-face treatment sessions. In these sessions, they were instructed on the techniques described above. Each session lasted 50 minutes. In both groups, the weekly sessions were conducted individually. Patients were randomly assigned to one of the two treatment groups; Figure 1 describes the randomization process and participant follow-up. Flowchart of the study process The treatment was conducted by two clinical psychologists with a master's degree in cognitive behavioral therapy (CBT) and training in the diagnosis and treatment of insomnia. The techniques implemented in the intervention were Stimulus Control Therapy (SCT), Sleep Restriction Therapy (SRT), Progressive Muscle Relaxation (PMR), and Sleep Hygiene (SH). For a more detailed description, please refer to the Appendices. Instruments and measurements Sleep Diary A sleep diary is the gold standard for recording subjective sleep quality, including sleep duration, naps, number of awakenings per night (Aw), subjective sleep quality (SSQ), and subjective sleep efficiency (SSE) [20]. Pittsburgh Sleep Quality Index (PSQI) This is a self-administered index with a total score between 0 and 21 points; a score above 5 points is interpreted as poor sleep quality; for Mexican validation, a Cronbach's alpha of 0.78 was obtained [21,22]. Insomnia Severity Index (ISI) This is a self-administered index with eight items on a Likert scale from 0 (not at all) to 4 (very severe) that assesses nighttime and daytime insomnia symptoms; a reliability coefficient of 0.84 was obtained for Mexican validation [23,24]. Generalized Anxiety Disorder 7 (GAD-7) This is a self-administered questionnaire that assesses the presence and severity of generalized anxiety symptoms using seven Likert-scale items ranging from 0 (not at all) to 3 (almost every day). The total score ranges from 0 to 21; a total score above 10 is considered generalized anxiety. A version validated for the Mexican population demonstrated high internal consistency, with a Cronbach's alpha of 0.80 [25]. Patient Health Questionnaire 9 (PHQ-9) This is a self-administered questionnaire that assesses the presence and severity of depressive symptoms using nine Likert-scale items, with a scale from 0 (not at all) to 3 (almost every day). The total score ranges from 0 to 27. These scores are interpreted as mild (total score 0 to 5), moderate (6 to 10), moderately severe (11 to 15), or severe (16 to 27). A Mexican validation obtained a reliability of 0.89 [26]. SF-36 Health Survey This is a self-administered scale that assesses patients' quality of life. It is divided into eight health-related dimensions, such as physical functioning, role-playing, bodily pain, general health, vitality, social functioning, and emotional and mental health. The first four dimensions are assessed using a Likert scale from 0 to 4; the other four dimensions are assessed using a dichotomous (yes/no) format. A Mexican validation showed high internal consistency (Cronbach's alpha of 0.93) [27]. Procedure Participants who met the inclusion criteria and agreed to participate provided written informed consent. They then underwent a semi-structured clinical interview conducted by trained research assistants, and the data obtained were added to the database. The randomization sequence was generated using a simple computerized randomization algorithm via the website www.randomizer.org, resulting in a 1:1 allocation ratio between the two treatment groups. The randomization sequence was generated by a statistician (PhD) independent of the study team before participant enrollment. Participant enrollment was performed by the principal investigator, who was unaware of the allocation sequence. Participant allocation to the interventions was performed by a Psychologist (PhD) independent of the research team, who had no involvement in participant enrollment or outcome assessment, thus ensuring allocation blinding. Participants were informed of their group assignment only after completing the initial assessment. Statistical analysis Although the Kolmogorov-Smirnov test indicated a deviation from normality, repeated measures ANOVA was retained for the following reasons: first, ANOVA is considered robust to violations of normality when sample sizes are approximately equal across groups and when the number of repeated measurements is limited, as is the case in the present study (three time points: pre-, post-, and follow-up) [28]. Second, the central limit theorem supports the use of parametric tests when deviations from the distribution are moderate rather than severe, particularly in the context of behavioral outcome measures [29]. Third, repeated measures ANOVA allows for the estimation of between-group differences and their 95% confidence intervals (CIs) over time, which is not directly available through fully nonparametric alternatives such as the Friedman test. However, we acknowledge this limitation and complement the parametric approach with Friedman's non-parametric test for within-group comparisons, as well as with effect size estimates (Hedges' G) accompanied by their 95% CIs, thus providing a more complete and interpretable picture of the results. Results A total of 17 participants were included in the study. Sociodemographic variables are presented in Table 1. The age of the BBII-TC group ranged between 20 and 40 years, while the age of the BBII-FF group was 23-40 years (mean = 35.12 (SD = 6.24) vs mean =34.9 (SD = 5.32), p > 0.55). No significant differences were found in most sociodemographic variables except for pharmacological treatment (p < 0.024) (Table 1). Table 1Sociodemographics, pharmacological treatment, and chronicity of symptoms of the sample (N=17).Parameters BBII-TC (n=7), n %BBII-FF (n=10), n %Total (N=17), n %X2 Sex Male 4 (57.1)6 (60)10 (58.8)0.557Female3 (42.8)4 (40)7 (41.2) Marital Status Single 4 (57.1) 4 (40)8 (47.0) 0.464Married 2 (28.5)4 (40)6 (35.2) Other1 (14.2)2 (20)3 (17.2) Educational attainment High School 0 (0)7 (70)7 (41.2) 0.056Bachelor’s Degree7 (100)3 (30)10 (58.8) Months since the onset of infection 1 - 6 1 (14.2)1 (10)2 (11.7) 0.6116 - 12 4 (57.1)2 (20)6 (35.4) 12 - 242 (28.5)7 (70)9 (52.9) Non-psychiatric pharmacological treatmentNone 3 (42.8)7 (70)10 (58.8) 0.024non-psychiatric medication 2 (28.5)2 (20)4 (23.6) Other treatment2 (28.5)1 (10)3 (17.6) Insomnia duration (months) 1 - 6 4 (57.1)1 (10)5 (29.5) 0.2636 - 12 3 (42.8)6 (60)9 (52.9) 12 - 240 (0)3 (30)3 (17.6) Depression duration (months) 1 - 6 6 (85.7) 7 (70)13 (76.4)0.246 - 12 1 (14.2)3 (30)4 (23.6) 12 – 240 (0)0 (0)0 (0) Anxiety duration (months) 1 - 6 5 (71.4)9 (90)14 (82.3)0.926 - 12 2 (28.5)1 (10)3 (17.7) 12 – 240 (0)0 (0)0 (0) Sociodemographics, pharmacological treatment, and chronicity of symptoms of the sample (N=17). Sleep diary scores and questionnaires When pooling all subjects, comparing pre, post, and follow-up measurements revealed a significant increase in subjective sleep time (SST), SSQ, and SES. In addition, there was a significant decrease in Aw along with a significant decrease in the ISI, PHQ-9, GAD-7, and PSQI scores (indicating improvement in sleep quality) and mental health, as well as a significant improvement in quality of life (SF-36). All of these changes were maintained to the three-month follow-up (Table 2). Table 2Comparison, and size of effect in insomnia symptoms, mental health, quality of life and sleep diary between pre-treatment, post-treatment and follow-up.p < 0.05 is considered statistically significantPre: pre-treatment; Post: post-treatment; FU: follow-up; SST: subjective sleep time; Aw: number of awakenings per night; SSQ: subjective sleep quality; SSE: subjective sleep efficiency; PHQ-9: Patient Health Questionnaire – 9; PSQI: Pittsburgh Sleep Quality Index; ISI: Insomnia Severity Index; GAD-7: Generalized Anxiety Disorder-7; SF-36: Short Form-36; Z: difference between an observed statistic and its hypothetical parameter; b: non-standardized coefficientParametersPre-Intervention scoresPost-Postintervention scores3-month follow-up scoresPre vs PostPost vs FUPre Vs FUMedian (rank)Median (rank)Median (rank)Zp